We analysed urine samples from the 2001/2002 pilot study of the German Environmental Survey on Children (GerES IV) for the concentrations of the di-n-butylphthalate (DnBP) metabolite mono-n-butylphthalate (MnBP) and the butlybenzylphthalate (BBzP) metabolite mono-benzyl-phthalate (MBzP). The study population consisted of 239 children (106 boys, 133 girls) aged between 2 and 14 years (median 8.5 years). We applied two calculation models to estimate the daily intake for the two parent phthalates from metabolite excretion. One was based on the creatinine-related metabolite concentrations; the other was based on the volume-related metabolite concentrations. Median urinary metabolite concentrations were 174 mg/l (136 mg/g creatinine) for MnBP and 19.7 mg/l (15.3 mg/g creatinine) for MBzP. Such levels have been determined in German children before. Compared to the USA, German median MnBP levels were about 3-10 times higher, whereas MBzP levels were in the same range. Median daily intakes calculated with the creatinine-based model were 4.07 (range: 0.66-76.4; 95th percentile: 14.9) mg/kg body weight (bw)/day for DnBP and 0.42 (range: 0.06-13.9; 95th percentile: 2.57) mg/kg bw/day for BBzP. Daily intakes calculated with the volume-based model were approximately two times higher with a median of 7.61 (range: 0.91-110; 95th percentile: 30.5) mg/kg bw/day for DnBP and a median of 0.77 (range: 0.05-31.3; 95th percentile: 4.48) mg/kg bw/day for BBzP. Using the creatinine model, 28 (11.7%) of the 239 children exceeded the TDI for DnBP of 10 mg/kg bw/day defined by the European Union. Employing the volume model, 89 (37.2%) children exceeded the TDI. For BBzP, no preventive limit values (TDI or RfD) were exceeded. For both phthalates and independent of the model, we found increasing daily intakes with decreasing age. Between 25% (creatinine model) and 50% (volume model) of the 2-4-year old children had daily intakes for DnBP above the TDI.
Introduction
Di-n-butylphthalate (DnBP) is used as a specialist plasticizer for resins and polymers such as polyvinyl chloride (PVC) often in combination with other high molecular weight phthalates. DnBP is used in the adhesive industry for latex and polyvinyl acetate (PVA) emulsions and as a solvent or additive in inks and dyes, sealants/grouting agents, nitrocellulose paints, film coatings and glass fibres. Fulfilling multiple purposes, DnBP is used in various consumer products like perfumes, pesticides, aerosol sprays, skin emollients and nail polishes (Kavlock et al., 2002a; ECB, 2004a; EFSA, 2005a) . In the pharmaceutical field it is used in the gastric juice-resistant coating of capsules both in the US and Europe (Koch et al., 2005a; FDA, 2006) . Over 90% of butylbenzylphthalate (BBzP) is used for plasticizing of PVC or other polymers having consumer and industrial uses such as floorings, sealants, coatings and paints. To a lesser extent BBzP is also used in food conveyor belts, vinyl gloves, food wraps and other products for food packaging (Kavlock et al., 2002b; ECB, 2004b; EFSA, 2005b) .
DnBP and BBzP have been demonstrated to exert endocrine disruption in rodents. Critical effects are related to functional and structural impairment of reproduction and development (Gray et al., 2000; Kavlock et al., 2002a, b; ECB, 2004a, b; Foster, 2006) . DnBP and BBzP produce a number of reproductive abnormalities like malformations of the epididymis and the external genitalia (hypospadias), undescended testicles (cryptorchidism), impaired spermatogenesis and a general reduction of male fertility (Wine et al., 1997; Mylchreest et al., 2000) . DnBP and BBzP cause signs of feminization (retention of nipples/areolae in male rodents) and a reduced anogenital distance (AGD) as a first indication of general demasculinization (Lee et al., 2004; Tyl et al., 2004; Foster, 2006) . On a cellular level, both phthalates lead to decreased fetal testicular levels of testosterone and insulinlike factor 3 (Insl3) and to increased serum levels of the follicle-stimulating hormone (FSH) (Nagao et al., 2000; Wilson et al., 2004) . Both DnBP and BBzP are also suspected to act as endocrine disruptors in humans (Skakkebaek et al., 2001; Fisher, 2004, Sharpe and Irvine, 2004) . In the EU DnBP and BBzP are classified as ''substances which should be regarded as if they impair fertility in humans'' (toxic to reproduction, category 2) (Directive 2003/36/EC).
An evaluation by the European Food Safety Authority (EFSA) in 2005 allocated a Tolerable Daily Intake (TDI) for DnBP of 10 mg/kg bw/day based on the end points impairment of germ cell development and structural changes in the mammary gland (Lee et al., 2004; EFSA, 2005a) . The TDI for BBzP was set at 500 mg/kg bw/day based on the end points testicular toxicity and reduction of the AGD (Tyl et al., 2004; EFSA, 2005b) . The Reference Dose (RfD) of the US EPA for DnBP of 100 mg/kg bw/day (Smith, 1953; EPA, 1990) and for BBzP of 200 mg/kg bw/day (NTP, 1985; EPA, 1993) have not yet been updated with the most recent science.
Phthalates are ubiquitous environmental contaminants (Shelby, 2002) . Exposure to phthalates can be monitored by determining specific metabolites in urine. People exposed to DnBP will excrete its monoester mono-n-butylphthalate (MnBP) and people exposed to BBzP will excrete monobenzylphthalate (MBzP) in urine (Anderson et al., 2001) . By this means, the broad and ubiquitous exposure of the general population to these and other phthalates has been proven (Blount et al., 2000; Koch et al., 2003a Koch et al., -c, 2005a Silva et al., 2004; CDC, 2005) . We have to consider numerous sources and routes of exposure to phthalates (e.g. foodstuff(s), air, dust and water) often contributing to exposure increments that differ for several orders of magnitude (Meek & Chan, 1994; Clark et al., 2003) . The urinary metabolites represent an integrative measure of this cumulative exposure. Thus, human biomonitoring and the measurement of specific metabolites in urine (Angerer and Weiss, 2002) is an ideal approach to determine the overall individual exposure to phthalates.
Some studies indicate that exposure to phthalates is higher in children than in adults (Meek and Chan, 1994; Brock et al., 2002; CDC, 2005; Koch et al. 2005b) . Furthermore, toxicity studies identify children as one of the most susceptible populations to the endocrine disrupting effects of phthalates (Carruthers and Foster, 2005; Foster, 2006) .
Based on internal exposure data acquired in the pilot study for the German Environmental Survey on Children (GerES IV), we calculated the daily intake levels for DnBP and BBzP. We related these daily intake levels to current risk and preventive limit values (TDI and RfD) . Through this approach we can give a better basis for the evaluation of a potential health risk for children due to the ubiquitous exposure to DnBP and BBzP.
Methods

Study Population
The urine samples had been collected as part of the pilot study for the German Environmental Survey on children (GerES IV) that had been carried out between March 2001 and March 2002 (Becker et al., 2004) . Two sampling locations were situated in two districts of the city of Berlin and two locations were in rural areas of northern Germany. Of the originally 550 children, first morning urine samples from 239 children aged 2-14 years (median 8.5 years) were analysed. Selection criteria were availability of a complete questionnaire including individual data on age, body weight and body height and a sufficient amount of urine and house dust (data not shown). Urine samples had been collected depending on the age group either by the parents or the children themselves in polypropylene or polyethylene containers (TYCO Healthcare, Kautex). Samples were then stored at cool places of the subjects' homes (usually in the fridge) until later on the same day the interviewer took the samples to the examination centre in an ice chest. Samples were aliquoted and frozen (À201C) in polypropylene tubes (Saarstedt). Between sampling and freezing of the sample, a median time of 6.5 h elapsed (range of about 1-12 h). The urine samples were coded and analysed in a randomized sequence to avoid any observer bias. Further information on GerES IV is provided by the German Environment Agency (UBA, 2005) .
Chemical Analysis
The first morning voids were analysed using two-dimensional liquid chromatography tandem mass spectrometry (LC/LC-MS/MS) with quantification by isotope dilution (Koch et al., 2003b; Preuss et al., 2005) . Internal quality control was performed by analysing a low and a high concentration native control urine (MnBP: 38.4 and 170 mg/l, MBzP: 4.86 and 31.6 mg/l) within each analytical series. Relative standard deviations were between 6.5% and 11.9%. The limit of quantification (LOQ) was 1.0 mg/l for MnBP and 0.5 mg/l for MBzP. Reagent blanks (two analysed within each analytical series, 22 over the whole study) were found to contain traces of MnBP. The overall mean blank value for MnBP was 1.8 mg/l (range 0.9-2.8 mg/l; standard deviation 0.56) and therefore considerably below the MnBP levels determined in native urine samples. To accommodate background contamination, results were corrected by subtracting the mean blank value plus three times its standard deviation.
Statistical Analysis
Descriptive statistics for the study population were performed with SPSS 12.0G (SPSS Inc., Chicago). We used Spearman rank correlation coefficients to analyse associations between age and urinary metabolite concentration, respectively, between age and daily intakes. To investigate differences between the two intake calculation models, we used simple linear regression and Pearson's correlation.
Daily Intake Calculations
Based on the urinary metabolite levels, we calculated the daily intake of the parent phthalate separately for each child. We applied two calculation models. The first model was based on the creatinine-related metabolite concentrations together with reference values for the creatinine excretion in children (Remer et al., 2002) . We performed the daily intake calculation by applying the following equation, which is derived from an equation used in previous daily intake calculations (David, 2000; Kohn et al., 2000; Koch et al., 2003a) UE sum is the molar urinary excretion of the respective metabolite in micromole per gram creatinine. The smoothed creatinine excretion rates CE smoothed are body height-and gender-based reference values for urinary creatinine excretion for healthy Caucasian children aged 3-18 years in gram creatinine per day taken from the study of Remer et al. (2002) . Taking account of the variability in creatinine excretion among children is essential for a valid estimation, because creatinine excretion has been shown to vary greatly among children of different ages, size, body weight (bw) gender and race (Remer et al., 2002; Barr et al., 2005) . We normalized these values to the body weight of every individual subject. The molar fraction F UE describes the molar ratio between the amount of metabolite excreted in urine and the amount of parent phthalate taken up. The F UE for DnBP and BBzP was determined by Anderson et al. (2001) after oral administration of labelled phthalate standards at two dose levels to human volunteers (six or seven volunteers per dose experiment) to be 0.69 for DnBP and 0.725 for BBzP, meaning that 69% of an oral dose of DnBP is excreted as urinary MnBP and 72.5% of an oral dose of BBzP as urinary MBzP. Individual variability in excretion for the two metabolites and the two dose levels was moderate with relative standard deviations between 26% and 39%.
Only a small amount of BBzP is excreted as MnBP (o6%), thus exposures to DnBP and BBzP can be measured independently within the general population without major confounding effects (Anderson et al., 2001) . MW Phthalate stands for the molecular weight of the respective phthalate (278 g/mole for DnBP and 312 g/mole for BBzP).
The second daily intake calculation model was based on volume-related urinary metabolite concentrations together with reference values for the mean daily body weight-related urine volume in children:
The urinary creatinine excretion also varies in children of different age, the mean excreted urine volume is a variable of age in children. The mean urine volume per kg body weight per day is generally decreasing with increasing age. We took this into account by using reference values regarding age for the daily excreted urinary volume UV norm which range from 0.019 to 0.035 l urine/kg bw/day (Geigy, 1977) .
Results and discussion
Metabolites in Urine
We detected and quantified the metabolites MnBP and MBzP in all 239 urine samples. For MnBP, volume-based urinary concentrations varied widely among the individual samples of the children and ranged from 15.5 to 3193 mg/l. Creatinine-adjusted levels of MnBP ranged from 16.8 to 2102 mg/g creatinine. Urinary MBzP concentrations were in the range from 0.93 to 744 mg/l and 1.78 to 567 mg/g creatinine, respectively. Median concentrations of MnBP were approximately 10 times higher than median concentrations of MBzP, both unadjusted and creatinine adjusted. Table 1 summarizes the descriptive statistics for the metabolites MnBP and MBzP.
So far, only a few studies on DnBP and BBzP metabolites in urine are available and these studies are restricted to the USA and Germany (Table 2 ). The National Health and Nutrition Examination Surveys (NHANES) collected data only from children of 6 years and older (CDC, 2005) . Only one German study (Koch et al., 2005b) and one study from the USA (Brock et al., 2002) investigated the internal DnBP and BBzP exposure of young children. Brock et al. (2002) found phthalate monoester levels in urine of infants (11.8-16.5 months old) comparable to the concentration range observed of the NHANES reference population. They, however, pointed out that relating the urinary metabolite levels of these children to their low body weights indicated an uptake of phthalate doses at least twice as high compared to the adult population. Median MnBP levels for the 239 children of GerES IV pilot study (this study) were about 3-10 times higher than in the US. Median MBzP levels for children were within the same order of magnitude.
Compared to metabolite levels previously determined in a small population of 36 German nursery school children, aged 2-6 years (Koch et al., 2005b) , metabolite levels determined in this pilot study were in good accordance. Internal MnBP and MBzP exposures correlated within the nursery school children (Spearman rank correlation coefficient r ¼ 0.72, Po0.001). This finding could be confirmed in this study with a Spearman rank correlation coefficient of r ¼ 0.40 (Po0.001). Both correlations were derived from the volumebased concentrations with similar results for the creatinineadjusted values. DnBP and BBzP seem to be equally distributed in the various sources of exposure, with higher levels for DnBP in Germany compared to the USA.
In two case studies both in the USA and in Germany, extraordinary high urinary MnBP concentrations (16.9 mg/l and 31.0 mg/l) were reported after DnBP-containing medications have been taken (Hauser et al., 2004; Koch et al., 2005a) . These values are about a 100-1000 times higher than the median values in all previously investigated populations. Table 3 presents the urinary MnBP and MBzP concentrations in mg/l separately for the 106 boys and the 133 girls. These two subpopulations showed no statistically significant differences. Table 4 presents the results for five different age groups in volume-related concentrations and adjusted for creatinine.
Regarding the values in mg/l, we could not observe an association between urinary metabolite concentrations and age by Spearman rank correlation (MnBP: r ¼ À0.01995, P ¼ 0.7590; MBzP: r ¼ À0.09029, P ¼ 0.1641), although both phthalate metabolites show the lowest median concentrations for the oldest children (age group 12-14). However, when comparing volume-related metabolite concentrations in urine of children of different ages and adults, one has to consider that infants produce about one-third of the urine volume of adults with about one-seventh of the body weight (Harper et al., 1977; Greene, 1991 , Brock et al., 2002 . Therefore, the same urinary metabolite concentrations (in mg/l) in children and adults extrapolate to higher exposure doses (in mg/kg bw/day) for children. These differences are aligning gradually during adolescence.
Regarding the values adjusted for creatinine, concentrations for the youngest children (age group 2-4 years) were about three times higher for both metabolites compared to the oldest children aged 12-14 years (244 versus 81.2 mg/g creatinine for MnBP and 22.3 versus 8.05 mg/g creatinine for MBzP) with the values for the other age groups in between. According to Sperman rank correlations, creatinine-adjusted concentrations were clearly decreasing with increasing age for MnBP (r ¼ À0.389; Po0.001) and for MBzP (r ¼ À0.365; Po0.001). It is important to note that creatinine-adjusted values for children, like the volume-related raw data, have to be interpreted with care as creatinine excretion of children strongly depends on gender, body weight and age (Geigy, 1977; Remer et al., 2002) . Creatinine adjustment that is often used as a measure of dilution of the urine, therefore, is also a measure of the rapidly changing physical properties within the population of children and an indicator of the different physical properties between children and adults.
Daily Intakes for DnBP and BBzP
We used two different calculation models (volume and creatinine based) to calculate the daily DnBP and BBzP intake individually for each child. Urine samples (24 h) would be the ideal source to calculate daily intake values from excreted metabolites. However, this approach is rather unrealistic in epidemiological studies, especially when young children are involved. Therefore, first morning voids or spot samples are generally the urine samples analysed for assessing human exposures to many chemicals (Barr et al., 2005) . Urinary concentrations in these spot urine samples have to be extrapolated to reflect the overall 24-metabolite excretion. These extrapolations to the 24h-metabolite concentration and finally to the original chemical taken in have to consider the different physical properties within the population of growing children and between children and adults. The two different calculation models (model 1 based on creatinineadjusted concentrations; model 2 based on volume-related concentrations) accommodate these different physical properties. In model 1, CE smoothed takes account of the daily urinary creatinine excretion depending on gender and height (Remer et al., 2002) ; in model 2, UV norm takes account of the urine volume depending on age and body weight (Geigy, 1977) . We used the metabolite conversion factors F UE (for the monoester metabolites MnBP and MMzB) determined in adults by Anderson et al. (2001) . However, the NTP-CERHR (Kavlock et al., 2006) has recently shown for DEHP that the ratio of oxidative metabolites to monoester metabolites changed almost linearly with age group (but not with sex and race/ethnicity). Children aged 6-11 years produced a smaller fraction (approximately 50% less) of the simple monoester metabolite compared to oxidative metabolites than adolescents or adults. For DnBP and BBzP, this would mean that in children the excretion of the simple monoesters MnBP and MBzP underestimate the actual exposure to the parent phthalate. For example, assuming a metabolite excretion factor F UE of 0.5 for MnBP instead of 0.69 would result in a 40% higher daily DnBP intake for children. Table 5 depicts the daily DnBP and BBzP intake values for the 239 children of the GerES IV pilot study separately for the two calculation models. For the creatinine-based model, the medians for DnBP and BBzP were 4.07 and 0.42 mg/kg bw/day, respectively. The 95th percentiles were 14.9 and 2.57 mg/kg bw/day, respectively. With the volumebased calculation model, we obtained a median daily intake for DnBP and BBzP of 7.61 and 0.77 mg/kg bw/day, respectively, and a 95th percentile of 30.5 and 4.48 mg/kg bw/day, respectively. The outcomes for the two models correlated strongly with a Pearson correlation coefficient of 0.90 (Po0.001) for DnBP and 0.94 (Po0.001) for BBzP. Regression slopes of 1.58 and 2.04, respectively, illustrate that values obtained by the volume-based calculation model were between 1.5 and 2 times higher than values obtained with the creatinine-based model. However, 22 out of the 239 children (9.2%) had higher daily intake values in the creatinine than in the volume model. Figure 1 illustrates the relative cumulative frequencies of daily DnBP intakes for all individuals for both calculation models. With the creatinine model, doses taken up by 28 (11.7%) of the 239 children exceeded the TDI; with the volume model, uptakes for 89 (37.2%) children exceeded the TDI. All TDI oversteppings revealed by using the creatinine model were affirmed by calculations with the volume model. One child, and only when using the volume model, exceeded the RfD of the US EPA. For BBzP, no child exceeded either of the preventive limit values. Maximum daily intakes for BBzP (13.9 mg/kg bw/day for the creatinine model and 31.3 mg/kg bw/day for the volume model) were considerably below the RfD of 200 mg/kg bw/day and the TDI of 500 mg/kg bw/day (see Table 5 ).
We can compare the daily intakes for DnBP and BBzP calculated in this study with only three previous studies based on urinary metabolite excretion. David (2000) and Kohn et al. (2000) calculated daily intakes for 289 adults from NHANES III in the USA, Koch et al. (2003a) for 85 subjects (also mainly adults) from the German population (Table 6 ). Calculations based on the creatinine model of this study confirm the daily intakes calculated previously by Koch et al. (2003a) for both DnBP and BBzP. For DnBP, daily intakes in the USA seem to be lower by a factor of 2-4, regarding median values and the 95th percentile. Maximum values, however, determined for the USA were exceeding the maximum values found in Germany. One possible explanation for these differences between the US and Germany can be differences in DnBP content in various products or different usage patterns. There are indications that in the US DnBP is replaced by DEP (diethylphthalate) because levels of DEP exposure are considerably higher in the US than in Europe (Koch et al., 2003a-c; Adibi et al., 2003) . Kavlock et al. (2002) point out that DnBP has not been used for a considerable time in the USA to plasticize PVC. Peak DnBP exposures can be caused through DnBP-containing medications both in the US (Hauser et al., 2004) and Germany (Koch et al., 2005a) . For BBzP, daily intake values are roughly the same in the USA and Germany over the whole range. All studies, therefore, have in common, that preventive limit values for DnBP (like the TDI and the RfD) can be exceeded on an individual basis, whereas daily intakes for BBzP are consistently below these limit values. The volume-based daily intakes of this study stand apart from all previous calculations, as these calculations have all been based on creatinine-adjusted metabolite concentrations. The volume-based model indicates (at least for the population of children) that creatinine adjustment tends to result in lower daily intake values and might at least for some individuals underestimate the daily DnBP and BBzP intake.
Looking closer into the population of the GerES IV pilot study, we found no statistically different daily intakes for boys and girls regarding both phthalates (Table 7) . Boys and girls exceeded the TDI for DnBP in equal shares.
For both phthalates, however, we found the daily intake values depending on age (see Table 8 ). With decreasing age daily intakes significantly increased, independent of the calculation model used. Comparing median values, the daily intake of the youngest children (2-4 years old) was approximately twice the daily intake of the oldest children included in this study (12-14 years old). This was true for both phthalates and for both calculation models. Spearman rank correlations for DnBP intake and age were r ¼ À0.280 (Po0.001) for the creatinine model and r ¼ À0.191 (P ¼ 0.003) for the volume model, indicating a low but still significant negative correlation. Spearman rank correlations for BBzP intake and age were r ¼ À0.274 (Po0.001) and r ¼ À0.227 (Po0.001), respectively.
Daily DnBP intakes for the five age groups (2-4, 5-6, 7-8, 9-11 and 12-14 years) within the 239 children are depicted in Figure 2 . Obvious, again, are the higher daily intake values for the volume-based model, and the decreasing daily intakes with increasing age in both models. The two core findings of this study can impressively be seen in this figure: between 25% and 50% of the 2-4-year-old children exceed the tolerable daily intake for DnBP; and independently of the model, some children in each of the age groups exceed the TDI value of the EFSA for DnBP. 
Conclusions
In this study, we present for the first time data on the urinary excretion of the specific metabolites of DnBP and BBzP in a larger population of young children. To avoid any misinterpretation it has to be stated that all data presented here, due to the pilot character of the study, cannot be regarded as representative for all German children. Owing to the rapidly changing physical properties of infants and adolescents biomonitoring data on metabolite concentrations in spot urine samples (both related to the urine volume and adjusted for creatinine) can only validly be compared with populations of the same demographic composition (Remer et al., 2002; Barr et al., 2005) . Generally speaking, however, DnBP exposures in Germany seem to be higher than in the USA as all available studies show. This difference is most probably founded in a different usage pattern for this phthalate in Germany/Europe and the USA. Production numbers for the various phthalates have shifted rapidly over the last years, and further shifts will occur due to public and political pressure. This is the first study to present daily intake values for children based on biomonitoring data. We used two different models for the calculation of the daily intakes for DnBP and BBzP in children based on metabolite concentrations in spot urine samples. With the current standard of knowledge, neither of the two calculation models is preferable and both approaches must be regarded equivalent at present time. Furthermore, we want to point out that both models are not based on worst case assumptions but try to accommodate the most likely exposure scenario for each individual child. As two case studies in the US and Germany have shown (Hauser et al., 2004; Koch et al., 2005a) , actual individual exposures to DnBP through medications can be manifold higher than reported in this study.
Obviously, the preventive limit values for DnBP differ considerably between Europe and the USA. However, it was only a most recent review of the latest data that lead to lowering the TDI in Europe by a factor of 10 (EFSA, 2005a). A considerable part of the 239 GerES IV children (pilot study) exceeded this TDI, and oversteppings were in part considerable (factor 10). Of utmost concern is that between 25% and 50% of the youngest children investigated had been exposed to DnBP in doses exceeding the TDI. Animal studies suggest that young children are one of the most susceptible subpopulation for the endocrine disrupting effects of phthalates (ECB, 2004a, b; EFSA, 2005a, b) . At exposures above or necessarily near the TDI, we cannot exclude adverse effects on reproduction and development any more. Table 6 . Comparison of the daily intake values (in mg/kg bw/day) deduced from urinary metabolite measurements in general population in our study and in those of Kohn et al. (2000) , David (2000) and Koch et al. (2003) David (2000) Kohn Of additional concern is that the children and the population in general is broadly exposed to other endocrine disrupting phthalates like BBzP, di(2-ethylhexyl)phthalate (DEHP) or di-iso-nonylphthalate (DiNP) (Koch et al., 2003a (Koch et al., -c, 2004 (Koch et al., , 2006 Becker et al., 2004; Silva et al., 2004 Silva et al., , 2006 . These phthalates (DnBP, BBzP, DEHP and DiNP) act on the same target organ (the testis), and produce a wide array of similar effects (Foster, 2006) . Although their individual modes of action have not yet been fully elucidated, it has to be presumed that cumulative exposures to these phthalates might also increase the risk for the development of endocrine disrupting/modulating effects. Gray et al. (2006) have shown that in utero exposure to a mixture of seven environmental antiandrogens (among them BBzP, DnBP and DEHP) reduced anogenital distance (AGD) in a linear 'dose additive' manner in neonatal male rats. As reductions in AGD in male rats are highly correlated with an increase in reproductive tract malformations (McIntyre et al., 2002; Hotchkiss et al., 2004) , it is likely that cumulative toxicity will be seen on other reproductive end points later in life, too.
We have shown that many children scoop out and exceed the preventive limit value for DnBP. Cumulative exposures to other endocrine active phthalates within the same order of magnitude are likely. Therefore, both the Risk Assessment Report of the European Chemical Bureau (ECB, 2004a) and the NTP-CERHR report on DnBP (Kavlock et al., 2002a ) might need to be updated to the most recent findings in the fields of exposure assessment, toxicology and epidemiology. Figure 2. Daily DnBP intakes as calculated by the volume-based (white boxes, foreground) and creatinine-based (grey boxes, background) calculation models, grouped by age.
